Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Non-Small-Cell Lung 249Breast Neoplasms 197Glioblastoma 196Lung Neoplasms 194Head and Neck Neoplasms 176Squamous Cell Carcinoma of Head and Neck 166Prostatic Neoplasms 164Lymphoma 152Rectal Neoplasms 131Central Nervous System Neoplasms 119Esophageal Neoplasms 117Leukemia 111Brain Neoplasms 99Pancreatic Neoplasms 95Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Gliosarcoma 86Esophageal Squamous Cell Carcinoma 83Lymphoma, Follicular 81Sarcoma 80Lymphoma, Large B-Cell, Diffuse 80Uterine Cervical Neoplasms 76Lymphoma, Non-Hodgkin 75Hodgkin Disease 73Neoplasms 68Burkitt Lymphoma 67Leukemia, Lymphocytic, Chronic, B-Cell 63Colorectal Neoplasms 63Glioma 61Astrocytoma 60Lymphoma, Large-Cell, Immunoblastic 58

Interventions

Radiosurgery 4Magnetic Resonance Spectroscopy 4luprolide acetate gel depot 3enzalutamide 3Radiotherapy 3Radiation 3Leuprolide 3Goserelin 3relugolix 2gallium 68 PSMA-11 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Triptorelin Pamoate 2Specimen Handling 2Biopsy 2radium Ra 223 dichloride 1niraparib 1histrelin 1fluciclovine F-18 1flibanserin 1entinostat 1darolutamide 1atezolizumab 1apalutamide 1abiraterone 1X-Rays 1Watchful Waiting 1Salicylic Acid 1Receptors, Bombesin 1Radium-223 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Prostate Adenocarcinoma × Radiotherapy × Clear all
NCT03274687 2026-05-20

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NRG Oncology

Phase 3 Completed
296 enrolled 29 charts
Genitourinary

Prostate Adenocarcinoma

NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT04175431 2025-12-18

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

University of Washington

Phase 2 Recruiting
100 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡